-
Sector Analysis
Immuno-oncology: Strategic Intelligence
This report includes coverage of immuno-oncology overview, trends, leading marketed and pipeline products, market analysis, regulatory landscape and market access, opportunities, challenges, and unmet needs, commercial assessment - major current and future players in the immuno-oncology field. The global market value for bispecific antibodies, cancer vaccines, checkpoint modulators, cell therapies, cytokines, and oncolytic viruses increased from $10.4 billion in 2014 to $74 billion in 2024. This growth trajectory is expected to continue, with the total market reaching $186 billion by...
-
Sector Analysis
Pancreatic Cancer in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, China, and Japan) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Pancreatic cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases. Key Highlights - Report deliverables include an Excel-based forecast model - Forecasts...
-
Sector Analysis
HER2-Negative Breast Cancer Epidemiology Analysis and Forecast to 2034
Breast cancer is a malignant tumor originating within the breast tissue. The most common type of breast cancer is invasive breast cancer, which originates from the milk ducts and invades the surrounding breast tissue (Cancer Research UK, 2023a). As it progresses, the cancer can metastasize to other parts of the body via the bloodstream and lymphatic system (American Cancer Society, 2022). According to the World Health Organization (WHO), breast cancer was the most common diagnosed cancer in women in 157...
-
Sector Analysis
Uveitis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the uveitis market through 2033. There will be an overall increase in the diagnosed prevalent cases of uveitis in the 7MM across the forecast period. Across the 7MM, the mainstay treatment for uveitis involves the use of anti-inflammatory therapies. Significant clinical unmet needs remain in the uveitis market. The late-stage uveitis pipeline consists of six agents. The uveitis market in the 7MM was valued at...
-
Sector Analysis
Spinal Muscular Atrophy Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Spinal Muscular Atrophy (SMA) market through 2033. The diagnosed prevalent cases of SMA across the seven major markets are expected to increase from 18,621 cases in 2023 to 19,202 cases by 2033. The SMA market across the 7MM was valued at $2.7 billion in the 2023 baseline year. Over the 10-year forecast period, the market is projected to grow at...
-
Thematic Analysis
Blockbuster Drugs on Patent Cliffs: Strategic Intelligence
A patent cliff occurs when a drug loses its patent protection, allowing biosimilars and generics to enter the market. This typically leads to a sharp drop in revenue for the originator company as market share declines. Pharmaceutical companies need to think about their business strategies to remain competitive and sustain profitability as patents expire. As a result, pharmaceutical companies will face increased pressure to innovate, diversify, and show a strong differentiated pipeline. The next patent cliff, between 2025 and 2030,...
-
Sector Analysis
Bio/Pharmaceutical Outsourcing Report, June 2025
The Bio/Pharmaceutical Outsourcing Report is a monthly analysis of news and trends affecting pharmaceutical Contract Manufacturing Organizations (CMOs). It includes in-depth analyses of the latest business conditions, lists new outsourcing contracts, assesses the latest opportunities and threats for manufacturers, and identifies recent mergers, acquisitions, and financing among CMOs. It also updates readers on facility-level news, such as planned site openings and closures, Good Manufacturing Practice (GMP) inspections, and investments in technology and equipment.
-
Sector Analysis
Clinical Trials:Â Biomarkers to Support Clinical Endpoints
This report provides a comprehensive analysis of biomarkers in clinical trials. The purpose of this report is to offer valuable insights into the landscape of clinical trials involving biomarkers by highlighting trends and patterns across various dimensions. Ultimately, this report serves as a resource for researchers, clinicians, and industry stakeholders seeking to understand the evolving role of biomarkers in clinical trials. The insights derived from this analysis can inform future research directions, enhance trial design, and contribute to feasibility planning. This...
-
Sector Analysis
Critical Assessment of Trump Administration’s Renewed Efforts to Introduce IRP in the US via the MFN Executive Order
In May 2025, US President Donald Trump issued an executive order (EO) stating that pharmaceutical companies should provide Most Favored Nation (MFN) prices to American consumers or face steep penalties. The EO calls for the introduction of International Reference Pricing (IRP) in the US. Based on extensive knowledge of IRP and detailed IRP 360 profiles for 75 markets, in this report GlobalData examines the implications of IRP use by the US for pharmaceutical companies, for payers, and for patient access...
-
Sector Analysis
Pulmonary Arterial Hypertension Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034
This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Pulmonary Arterial Hypertension market through 2034. GlobalData estimated that drug sales for PAH in 2024 were approximately $7.65 billion across the 7MM. With an estimated $5.83 billion in drug sales in 2024, the US dominated the PAH market, contributing 76.3% of the sales in the 7MM. This high market share is primarily due to the large PAH prevalent population and...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.